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The adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR) (hereafter referred to as CAR-T cells) specific for the B lymphocyte antigen CD19 has shown impressive clinical responses in patients with refractory B cell malignancies [1] [2] [3] [4] [5] [6] [7] . However, the therapeutic effects of CAR-T cells that target other malignancies have not yet resulted in significant clinical benefit [8] [9] [10] [11] . Although inefficient tumor trafficking and various immunosuppressive mechanisms can impede CAR-T cell effector responses, the signals delivered by the current CAR constructs may still be insufficient to fully activate antitumor T cell functions. Optimal T cell activation and proliferation requires multiple signals, including T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2) and cytokine engagement (signal 3) 12 . However, CAR constructs currently being tested in the clinic contain a CD3z (TCR signaling) domain and co-stimulatory domain(s) but not a domain that transmits signal 3 (refs. 13-18) . Here we have developed a novel CAR construct capable of inducing cytokine signaling after antigen stimulation. This new-generation CD19 CAR encodes a truncated cytoplasmic domain from the interleukin (IL)-2 receptor b-chain (IL-2Rb) and a STAT3binding tyrosine-X-X-glutamine (YXXQ) motif, together with the TCR signaling (CD3z) and co-stimulatory (CD28) domains (hereafter referred to as 28-∆IL2RB-z(YXXQ)). The 28-∆IL2RBz(YXXQ) CAR-T cells showed antigen-dependent activation of the JAK kinase and of the STAT3 and STAT5 transcription factors signaling pathways, which promoted their proliferation and prevented terminal differentiation in vitro. The 28-∆IL2RB-z(YXXQ) CAR-T cells demonstrated superior in vivo persistence and antitumor effects in models of liquid and solid tumors as compared with CAR-T cells expressing a CD28 or 4-1BB co-stimulatory domain alone. Taken together, these results suggest that our new-generation CAR has the potential to demonstrate superior antitumor effects with minimal toxicity in the clinic and that clinical translation of this novel CAR is warranted.
Cytokines that share common γ-chains in their receptors have a fundamental effect on T cell immunity, mainly through activation of the JAK-STAT signaling pathway 19 . Whereas IL-2, IL-7 and IL-15 predominantly induce STAT5 activation through tyrosine residues within the common γ-chain, the IL-2R β-chain (for IL-2 and IL- 15) or the IL-7R α-chain (for IL-7), IL-21 preferentially activates STAT3 through its association motif YXXQ within the IL-21 receptor 20 . In addition to its critical role in memory cell formation and effector cell differentiation, IL-21 functions synergistically with other cytokines to promote T cell proliferation [21] [22] [23] . Indeed, the forced expression of cytokine-encoding genes in CAR-T cells improves their persistence and antitumor effects in vivo, highlighting the importance of signal 3 for CAR-T cell functions [24] [25] [26] . However, constitutive cytokine expression poses a risk for autonomous T cell growth, potentially causing cancers, as well as for serious adverse events such as cytokine release syndrome (CRS) and neurotoxicity by CAR-T cells with excessive growth potential 27, 28 . Here we aimed to determine whether delivery of cytokine signaling only after antigen engagement could enhance antitumor effects of CAR-T cells.
To induce JAK-STAT pathway activation in CAR-T cells in an antigen-dependent manner, we first incorporated a full-length or truncated cytoplasmic domain of IL-2Rβ between the cytoplasmic domains of CD28 and CD3z ( Fig. 1a and Supplementary Table 1 ). Second, we added a YXXQ motif at the C terminus of CD3z for STAT3 recruitment (to obtain 28-IL2RB-z(YXXQ) or 28-∆IL2RBz(YXXQ)) 29 . We also generated CAR constructs with only a CD28 and CD3z cytoplasmic domain (construct 28-z) or a 4-1BB and CD3z cytoplasmic domain (BB-z) for comparison. A CD19-specific monoclonal antibody (clone FMC63)-derived single-chain variable fragment (scFv) targeting CD19 was used for antigen recognition 30 . All CAR constructs were N-terminally linked to a truncated version of nerve growth factor receptor (∆NGFR) via a 2A peptide sequence derived from porcine teschovirus 1 (P2A). The 28-∆IL2RB-z(YXXQ), but not the 28-IL2RB-z(YXXQ), CAR was efficiently expressed on the cell surface, specifically in the ∆NGFR + T cell population, and it transmitted T cell activation signals comparable to those of the A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects 28-∆IL2RBz(YXXQ) 28-z BB-z IL-2 IL-21 Figure 1 Generation of the CD19-specific chimeric antigen receptor constructs to induce JAK-STAT pathway activation. (a) A schematic diagram of the anti-CD19 CAR constructs used in this study. An FMC63-derived scFv was linked to CD28 and CD3z (to generate 28-z), to CD8-α, 4-1BB and CD3z (to generate BB-z), or to CD28, the cytoplasmic domain of the IL-2R β-chain, with or without an internal deletion, and CD3z with the YXXQ motif (to generate 28-IL2RB-z(YXXQ) and 28-∆IL2RB-z(YXXQ), respectively). All of the CARs were linked to truncated NGFR (∆NGFR) via a P2A sequence. (b,c) Representative FACS plots (b) and mean fluorescence intensity (MFI) of phosphorylated STAT3 and STAT5 within the CD8 + ∆NGFR + T cell population over time as assessed by flow ctyometry (c) in T cells that were transduced with the indicated CAR-encoding construct and stimulated with the CD19 + ALL cell line NALM-6 or the CD19cell line K562 at an effector to target (E:T) cell ratio of 1:1 (n = 4 different donor samples). T cells that were mock-transduced and treated with IL-2 (300 IU/ml) or IL-21 (50 ng/ml) were used as a control. P values were determined by repeated measures one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test for each time point (F = 63.57 (pSTAT3 at 60 min), 39.49 (pSTAT3 at 120 min), 71.41 (pSTAT3 at 240 min), 103.8 (pSTAT5 at 60 min), 201 (pSTAT5 at 120 min) and 113.7 (pSTAT5 at 240 min); degrees of freedom = 15). (d) Schematic representation of CAR constructs with either the STAT3-or STAT5-binding domain alone. For the 28-∆IL2RB(FLSL)-z(YXXQ) CAR, tyrosine within the YLSL motif of IL-2Rβ was replaced by phenylalanine to abrogate STAT5 association and the YXXQ motif was introduced by sitedirected mutagenesis to the C terminus end of CD3z. The 28-∆IL2RB-z CAR contains the intact STAT5-binding motif YLSL but not the YXXQ motif for STAT3 recruitment. (e) Quantification of STAT3 and STAT5 phosphorylation in T cells that were transduced with constructs encoding the indicated CARs 120 min after stimulation with NALM-6 (n = 4 different donor samples). P values were determined by repeated-measures one-way ANOVA with Tukey's multiple comparisons test; n.s., not significant; F = 75.44 for pSTAT3, F = 99.46 pSTAT5; degrees of freedom = 11. In c,e, horizontal lines denote mean values. l e t t e r S 28-z and BB-z CARs after encountering antigen, as demonstrated by CD69 upregulation and phosphorylation of the kinases ERK and Akt (Supplementary Figs. 1a,b and 2a-c). The 28-∆IL2RBz(YXXQ) CAR-T cells showed a significant upregulation of phosphorylated STAT3 (pSTAT3) and pSTAT5 in an antigen-dependent manner (Fig. 1b,c and Supplementary Fig. 3a,b) . Although STAT3 and STAT5 phosphorylation was also observed in CAR-negative T cells after antigen stimulation, expression of the 28-∆IL2RB-z(YXXQ) CAR triggered higher levels of pSTAT3 and pSTAT5 in CAR-positive cells, suggesting that the phosphorylation event was likely induced by cell-intrinsic signaling (Supplementary Fig. 4a-d) . Replacement of tyrosine by phenylalanine within the STAT5-association motif Tyr-Leu-Ser-Leu (YLSL) of the IL-2Rβ domain (28-∆IL2RB(FLSL)z(YXXQ)) significantly reduced pSTAT5 levels, and the deletion of the YXXQ motif at the C terminus (28-∆IL2RB-z) decreased pSTAT3 levels ( Fig. 1d,e and Supplementary Fig. 5a-c) . These results suggested that the YLSL and YXXQ motifs mainly contributed to the enhanced pSTAT5 and pSTAT3 levels, respectively. On the basis of these data, we further analyzed the functional attributes of the 28-∆IL2RB-z(YXXQ) CAR-T cells.
After in vitro antigen stimulation, the 28-∆IL2RB-z(YXXQ) CAR-T cells achieved significantly greater proliferation than the 28-z and BB-z CAR-T cells, regardless of cytokine supplementation, which resulted from both more rapid cellular division and less activationinduced cell death ( Fig. 2a-c and Supplementary Fig. 6a,b) . Both the STAT3-interaction and STAT5-interaction domains were required to promote CAR-T cell proliferation ( Fig. 2a and Supplementary  Fig. 6a ). Of note, the CAR-T cells with the STAT3-association motif maintained the less differentiated CD8 + CD45RA + CD62L + CCR7 + T cell population significantly better than the other CAR-T cells ( Fig. 2d and Supplementary Fig. 7 ). T cells within this population mostly expressed CD27, CD28 and CD95, which corresponded to a marker phenotype for stem-cell-like memory T cells 31 . Consistent with these results, cotreatment with the STAT3 inhibitor S3I-201 and the STAT5 inhibitor pimozide abrogated the proliferative advantage of the 28-∆IL2RB-z(YXXQ) CAR-T cells, and inhibition of STAT3 signaling in the 28-∆IL2RB-z(YXXQ) CAR-T cells decreased the CD45RA + CD62L + CCR7 + population ( Fig. 2e and Supplementary  Fig. 8a-c) . Although STAT3 activation can promote expression of programmed cell death ligand 1 (PD-L1) in several types of tumor cells, such as lymphoma cells and lung cancer cells 32, 33 , JAK-STAT pathway activation did not have effects in addition to those seen after antigen stimulation for the upregulation of PD-L1 or other immunoinhibitory molecules in antigen-stimulated CAR-T cells ( Supplementary  Fig. 9 ). After repeated stimulations, all CAR-T cells showed reduced proliferation and cytokine production and upregulation of certain exhaustion markers ( Supplementary Figs. 10 and 11) . These results suggest that retrovirally transduced CAR-T cells undergo functional impairment accompanied by chronic antigen exposure, as reported previously 34, 35 . 28-z CAR-T cells showed substantially decreased proliferation and increased expression of programmed cell death 1 (PD-1), lymphocyte activation gene 3 (LAG-3) and T cell immunoglobulin and mucin domain 3 (TIM-3), as compared with that of the BB-z and 28-∆IL2RB-z(YXXQ) CAR-T cells. 28-∆IL2RB-z(YXXQ)-or 28-∆IL2RB (FLSL)-z(YXXQ)-CAR-transduced CD8 + T cells maintained better proliferation, IL-2 secretion and cytokine polyfunctionality than other CAR-T cells. These attributes have been described in less differentiated memory T cells 36, 37 . To compare CAR-T cell functions after exposure to antigen in vivo, CAR-T cells were transplanted into immunodeficient NOD-SCID IL-2Rγ null (NSG) mice bearing tumors derived from NALM6 human leukemia cells ( Fig. 2f) . Persisting CAR-T cells were isolated from the spleen and analyzed for proliferative capacity and cytokine secretion ex vivo. Similar to the in vitro data, the 28-∆IL2RB-z(YXXQ) CAR-T cells showed better proliferation and cytokine polyfunctionality than the 28-z and BB-z CAR-T cells ( Fig. 2g,h) . These results suggest a key role of STAT3 in suppressing terminal differentiation of T cells, which is consistent with recent human and mouse studies 38, 39 .
To assess the genetic mechanisms underlying the functional properties of the 28-∆IL2RB-z(YXXQ) CAR-T cells, we compared the gene expression profiles of CD8 + CAR-T cells at 4, 24 and 72 h following antigen stimulation in vitro. The number of differentially expressed genes among the 28-z, BB-z and 28-∆IL2RB-z(YXXQ) CAR-T cells progressively increased over time ( Supplementary Table 2 ). Unsupervised hierarchical clustering and principal component analysis of those genes mostly classified different CAR-T cells into independent subclusters ( Fig. 3a,b) . We further investigated whether the 28-∆IL2RB-z(YXXQ) CAR induced gene expression profiles that reflected JAK-STAT pathway activation. Gene set enrichment analysis (GSEA) revealed significant enrichment of genes induced by IL-21 (but not by IL-2, IL-7 or IL-15) in the 28-∆IL2RB-z(YXXQ) CAR-T cells at 24 h after stimulation ( Fig. 3c and Supplementary Fig. 12a ). Moreover, the 28-∆IL2RB-z(YXXQ) CAR-T cells were enriched for expression of previously identified STAT3 target genes ( Fig. 3d) 40 , which further corroborated that STAT3 pathway was preferentially activated by the 28-∆IL2RB-z(YXXQ) CAR. These profiles were not evident at 4 h, and were maintained at 72 h, after activation ( Supplementary Fig. 12b,c) . Notably, the 28-IL2RB-z(YXXQ) CAR-T cells also showed increased expression of multiple genes encoding effector molecules, such as GZMA, GZMB, GZMH, GZMK and PRF1, which we validated by qPCR analysis (Fig. 3e) . We then evaluated the cytolytic efficacy of the 28-∆IL2RB-z(YXXQ) CAR-T cells relative to that of the other CAR-T cells. All of the CAR-T cells demonstrated similarly potent in vitro cytotoxicity against CD19 + cells ( Supplementary Fig. 13 ). However, the 28-∆IL2RB-z(YXXQ) CAR-T cells showed superior cytolytic activity following repeated antigen exposures, treatments that progressively attenuated the effector functions of the other CAR-T cells as previously reported ( Fig. 3f,g) 35 .
Next we studied the antileukemic potency of the 28-∆IL2RBz(YXXQ) CAR-T cells in vivo. NSG mice were treated with 5 × 10 6 CAR-T cells on day 14 after injection with 5 × 10 6 NALM6 cells that had been transduced with a construct expressing an EGFP-firefly luciferase fusion protein (hereafter referred to as NALM6-GL cells) (Fig. 4a) . The 28-∆IL2RB-z(YXXQ)-transduced T cells efficiently suppressed leukemia progression as compared to that with the 28-z and BB-z CAR-T cells, which resulted in significantly longer overall survival of the 28-∆IL2RB-z(YXXQ) CAR-T cell-treated mice (Fig. 4b,c and Supplementary Fig. 14) . Notably, the 28-∆IL2RBz(YXXQ) CAR-T cells showed significantly better persistence in the peripheral blood ( Fig. 4d) . Two infusions of CAR-T cells (5 × 10 6 cells per infusion, separated by 2 d) resulted in better control of leukemia and higher levels of secreted IL-2, interferon (IFN)-γ and tumor necrosis factor (TNF)-α with all of the tested CAR constructs, although the 28-∆IL2RB-z(YXXQ) CAR-T cells showed better persistence than the other CAR-T cells (Supplementary Fig. 15a-g) . 21) . (e-g) NSG mice were intravenously infused with CD19 + primary B-ALL cells (day -35) and adoptively transferred with 5 × 10 5 BB-z or 28-∆IL2RB-z(YXXQ) CAR-T cells (day 0). The serial monitoring of the CD45 + CD19 + B-ALL cells in the peripheral blood (n = 5 mice per group) (e), the Kaplan-Meier curve for the event-free survival of the mice (n = 5 mice group) (f) and the frequency of the CD8 + CAR-T cells in the peripheral blood on days 7, 14 and 28 (n = 5 mice per group) (g) are shown. In f, P values were determined by log-rank test, adjusted with Bonferroni correction. In g, P values were determined by unpaired two-tailed t-test (t = 2.58 for day 7; t = 4.28 for day 14; t = 2.46 for day 21; degrees of freedom = 8). The data are representative of two experiments using different B-ALL samples. (h) Experimental design. NSG mice were subcutaneously (s.c.) injected with the CD19-expressing A375 melanoma cells (A375-CD19) (day -21) and then treated with 5 × 10 5 CAR-T cells on days 0 and 4. (i-k) Frequency of CD8 + CAR-T cells in the peripheral blood and subcutaneous tumors on day 7, tumor progression (j) and overall survival (k) of mice treated as described in h (n = 7 mice per group). In i, P values were determined by ordinary one-way ANOVA with Tukey's multiple comparisons test (F = 12.61 for peripheral blood; F = 27.46 for tumor; degrees of freedom = 20). In k, P values were determined by log-rank test, adjusted with Bonferroni correction. Representative results of two experiments are shown. In d,g,i, horizontal lines indicate mean values ± s.d. *P < 0.001 by the statistical test indicated in the respective legend. l e t t e r S some mice after leukemia eradication (Supplementary Fig. 16a,b and Supplementary Table 3 ). The 28-∆IL2RB-z(YXXQ) CAR-T cells did not increase the development of GVHD as compared to that in mice treated with the 28-z and BB-z CAR-T cells. Indeed, all CAR-T cells induced similar progressive weight loss with comparable latency when infused into tumor-free mice (Supplementary Fig. 17a ). There was no significant difference in the development of lethal GVHD among 28-z, BB-z and 28-∆IL2RB-z(YXXQ) CAR-T cells ( Supplementary  Fig. 17b,c) . These results suggest that the 28-∆IL2RB-z(YXXQ) CAR does not affect endogenous TCR-mediated toxicity.
We also compared the efficacy of the BB-z and 28-∆IL2RB-z(YXXQ)-T cells against primary CD19 + B-ALL cells in vivo. The presence of CAR-T cells markedly delayed the progression of leukemia (Fig. 4e) . Similar to the results obtained with the mice with NALM6-GL-induced leukemia, the 28-∆IL2RB-z(YXXQ) CAR-T cells showed better persistence in peripheral blood and prevented leukemia progression for longer periods than the BB-z CAR-T cells (Fig. 4f,g) . Finally, we tested whether the JAK-STAT pathway activation in the CAR-T cells could improve their therapeutic effects against solid tumors. We adoptively transferred various CAR-engineered T cells into NSG mice that had subcutaneously been inoculated with A375 melanoma cells transduced with CD19 (A375-CD19) (Fig. 4h) . As was seen in the mouse models of leukemia, the 28-∆ILRB-z(YXXQ) CAR-T cells showed superior expansion in the peripheral blood and tumor mass, which resulted in better control of the tumor cells ( Fig. 4i-k) . At the time of the death of the mice, the tumor cells maintained CD19 expression, and the CAR-T cells had almost disappeared within the tumor mass, suggesting that the sustained persistence of CAR-T cells is required to suppress tumor progression (Supplementary Fig. 18a-c) .
In summary, we have developed a novel CAR construct that activates the JAK-STAT pathway. The 28-∆IL2RB-z(YXXQ) CAR triggered gene expression profiles analogous to those triggered by IL-21 treatment, which provided the T cells with distinct functional properties, including superior proliferative capacity and effector functions as compared to 28-z and BB-z CAR-T cells. Improved expansion of the 28-∆IL2RB-z(YXXQ) CAR-T cells in vivo could potentially increase the risk for CRS, which should be cautiously addressed when this construct is clinically translated. Our novel CAR design can be used in any CAR-T cell, independent of antigen specificity, to enhance their antitumor efficacy.
MeTHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINe MeTHODS
Construction of CAR-expressing genes. The 28-z CAR-encoding gene was generated by linking the sequences encoding the FMC63-derived scFV to those of the extracellular, transmembrane and cytoplasmic domain of CD28 (amino acids 114-220) and the cytoplasmic domain of CD3z. The BB-zencoding CAR was generated by inserting the sequences encoding the hinge and transmembrane domain of CD8-α and the 4-1BB cytoplasmic domain between the sequences encoding the scFV and cytoplasmic domain of CD3z. To induce JAK-STAT signaling in the CAR, the cytoplasmic domain of fulllength (amino acids 266-551) or truncated (amino acids 266-337 and 530-551) IL-2Rβ was linked between CD28 and cytoplasmic domain of CD3z. The YXXQ motif was created by site-directed mutagenesis at the C terminus region of CD3z domain. For the 28-∆IL2RB (FLSL)-z(YXXQ) CAR, tyrosine within the YLSL motif was substituted with phenylalanine to abrogate STAT5 recruitment. All CAR-encoding genes were linked to the sequence encoding ∆NGFR using a furin-Ser-Gly-Ser-Gly-P2A sequence and cloned into the pMX vector. The amino acid sequences of the CAR signaling domains are provided in Supplementary Table 1 .
In vitro culture of human T cells. Peripheral blood mononuclear cells obtained from healthy donors were prepared by Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare). The CD3 + and CD8 + cells were purified through negative magnetic selection using the Pan T Cell Isolation Kit and the CD8 + T Cell Isolation Kit (Miltenyi Biotec), respectively. The purified T cells were stimulated with irradiated artificial antigen-presenting cells that expressed a membrane-bound form of anti-CD3 (clone OKT3) and the co-stimulatory molecules CD80 and CD83 (aAPC/mOKT3 cells) at an E:T cell ratio of 5:1. On the following day, 100 IU/ml IL-2 and 10 ng/ml IL-15 (PeproTech) were added to the cultures. The culture medium was replenished every 2-3 d. CAR-transduced T cells were restimulated with NALM-6 or K562 at an E:T cell ratio of 1:1 7 d after the initial stimulation. The number of CAR-T cells was determined by calculating the product of the total number of T cells and the percentage of ∆NGFR + CD4 + or CD8 + T cells. The fold expansion was calculated by dividing the number of expanded CAR-T cells after 7 d of culture by the respective number on day 0.
Cell lines. Both aAPC/mOKT3 and K562-CD19 are derived from the human erythroleukemic cell line K562 (American Type Culture Collection; ATCC) and were established as previously described 41 . The CD19 + B-ALL cell line NALM-6 was obtained from DSMZ (Braunschweig, Germany). The A375 melanoma cell line was obtained from the ATCC. All cell lines were routinely assessed for the presence of mycoplasma contamination using a PCR-based technology.
Retroviral transduction of T cells. PG13 packaging cells stably transduced
with each retrovirus CAR-expressing plasmid were used for the infection of the T cells. The transduction was performed on days 2, 3 and 4 following the stimulation with aAPC/mOKT3 using polybrene at a concentration of 1 µg/ml. BD Biosciences), APC-anti-CD45 (clone HI30; BioLegend), FITC-anti-HLA-A2 (clone BB7.2; BioLegend) and PE-anti-CD19 (clone HIB19, BioLegend). The CAR-transduced T cells were stained with biotin-labeled protein L (GenScript), followed by streptavidin-PE (Thermo Fisher Scientific). For the CFSE dilution assay, T cells were labeled with 5 µM CFSE (Thermo Fisher Scientific) before culture. Dead cells were discriminated with the LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher Scientific). The stained cells were analyzed with a FACSCanto II instrument (BD Biosciences). The data analysis was performed using the FlowJo software (Tree Star).
Analysis of phosphoproteins by intracellular flow cytometry.
Phosphorylated proteins in the CAR-T cells were analyzed by intracellular flow cytometry following coculture with NALM-6 or K562 cells at an E:T cell ratio of 1:1. The cells were fixed with 1.6% formaldehyde, followed by permeabilization by ice-cold methanol. The following antibodies were used: Alexa-Fluor-647conjugated anti-phospho-STAT3(Tyr705) (clone 4/P-Stat3, BD Biosciences), Alexa-Fluor-647-conjugated anti-phospho-STAT5(Tyr694) (clone 47/Stat5, BD Biosciences), Alexa-Fluor-647-conjugated anti-phospho-p44/p42 MAPK (Erk1/Erk2) (Thr202/Tyr204) (clone 20A, BD Biosciences) and anti-phospho-Akt(Thr308) (clone D25E6, Cell Signaling Technology). Alexa-Fluor-647-conjugated anti-rabbit IgG (H+L) (Jackson ImmunoResearch) was used as the secondary antibody following the staining with the anti-phospho-Akt antibody. The STAT3 inhibitor S3I-201 (Selleck Chemicals) and the STAT5 inhibitor pimozide (Cayman Chemical) were used at concentrations of 25 µM and 5 µM, respectively.
Immunoblotting analysis. Equal amounts of protein were separated on 8% gels by SDS-PAGE and transferred to Immobilon-P PVDF membranes (Millipore). The membranes were probed with the primary antibodies at 4 °C overnight and then washed and incubated with horseradish peroxidase (HRP)conjugated goat anti-mouse-IgG (H+L) or anti-rabbit-IgG (H+L) secondary antibody (Promega). The following primary and secondary antibodies were used: anti-STAT3 (clone D3Z2G, Cell Signaling Technology; 1:1,000 dilution), anti-phospho-STAT3(Tyr705) (clone D3A7, Cell Signaling Technology; 1:1,000 dilution), anti-STAT5 (Cell Signaling Technology; 1:1,000 diltuion), anti-phospho-STAT5(Tyr694) (clone D47E7, Cell Signaling Technology; 1:1,000 dilution), anti-β-actin (clone C4, Santa Cruz Biotechnology, sc-47778; 1:1,000 dilution), HRP-conjugated anti-mouse-IgG(H+L) (Promega, W4021; 1:1,000 dilution) and HRP-conjugated anti-rabbit-IgG(H+L) (Promega, W4011; 1:1,000 dilution). All images were acquired with ChemiDoc MP system (Bio-Rad) and Image Lab software (Bio-Rad). Protein levels for each blot were quantified with ImageJ software.
Cytokine production analysis. For intracellular cytokine staining, CAR-T cells were stimulated with NALM-6 cells at an E:T cell ratio of 1:1. Brefeldin A (BioLegend) was added to the culture medium after 2 h to inhibit extracellular secretion of cytokines, and the cells were further cultured for 4 h. After staining for the surface markers, the cells were fixed and permeabilized using the Cytofix/Cytoperm Kit (BD Biosciences) and then stained with FITC-anti-IL-2 (clone 5344.111; BD Biosciences), PE-anti-TNF-α (clone MAb11; BioLegend) and PE-Cy7-anti-IFN-γ (clone 4S.B3; BioLegend). The frequency of cytokineproducing cells within the CD8 + ∆NGFR + T cell population was determined by flow cytometry.
In vitro cytotoxicity assay. The cytolytic activity of the CAR-transduced T cells was analyzed as previously described 42 . Briefly, 1 × 10 5 CAR-T cells were cocultured with an equal number of CFSE-labeled or EGFP + target cells for 4 h. The cells were then harvested and stained using the LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher Scientific). The absolute counts of the viable target cells were determined by flow cytometry, and the frequency of the surviving cells was calculated as a ratio to the cell counts obtained after incubation without T cells.
Microarray analysis. The CAR-transduced CD8 + T cells were cocultured with NALM-6 cells and purified at 4, 24 and 72 h after stimulation using a FACSAria cell sorter (BD Biosciences). RNA was extracted from the sorted cells using the 1 nature research | life sciences reporting summary Corresponding author(s): Naoto Hirano Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
Samples sizes were estimated based on preliminary experiments. We did not use a statistical method to predetermine sample size.
Data exclusions
Describe any data exclusions.
No data were excluded throughout the studies.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
The in vitro data were reproduced in multiple (at least three) samples. For in vivo studies to see antitumor effects of CAR-T cells, we repeated experiments twice and obtained similar results.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For in vivo studies, mice were randomly assigned to treatment groups in each experiment.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to group allocation during data collection or analysis. All of our data analysis both in vitro and in vivo is based on the objectively measurable data: absolute cell counts, frequency, fluorescence intensity, body weight, tumor size, and survival. Blinding does not affect these data values.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
